Sanofi-Aventis said that lixisenatide, an experimental Type 2 diabetes drug, has been very successful in a late stage trial at helping patients reduce their blood sugar levels and lose weight, according to a recent article from Reuters, as reported by Diabetes Newshound.
The study also found that the drug didn’t raise patients’ risk of hypoglycemia compared to a placebo.
The drug works by stimulating the pancreas to release extra insulin when blood sugar levels run too high. If the drug received FDA approval, it would compete against Victoza and Amylin from Novo Nordisk and Byetta from Eli Lilly.
